Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_assertion description "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_assertion evidence source_evidence_literature NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_assertion SIO_000772 26178788 NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_assertion wasDerivedFrom befree-2016 NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_assertion wasGeneratedBy ECO_0000203 NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- befree-2016 importedOn "2016-02-19" NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.